The groundbreaking rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its future within the broader market now raises questions about long-term gains. Generic versions are undercutting exclusivity , prompting concerns that investing in companies significantly dependent to Viagra's former standing could be a problema